Anacor Begins Phase 2b Study Of AN0128 In Children

... Anacor Pharmaceuticals, a privately held pharmaceutical company, announced today that it has begun dosing patients in its phase 2b study of AN0128, a novel topical anti-inflammatory drug candidate for atopic dermatitis (AD), a disease affecting approximately 15 million Americans. AD is characterized by a chronic rash with accompanying inflammation and infection. [click link for full article] ...